A Study of SBRT in Combination With rhGM-CSF for Stage IV NSCLC Patients Who Failed in Second-line Chemotherapy
Status:
Withdrawn
Trial end date:
2019-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether stereotactic body radiotherapy (SBRT)
combined with recombined human granulocyte-macrophage colony stimulating factor(rhGM-CSF) is
safe, effective in the treatment of stage IV NSCLC patients who failed in second-line
chemotherapy.